Asset Details
Do you wish to reserve the book?
S.L. patient backs attempt to bring drug for MS back
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
S.L. patient backs attempt to bring drug for MS back
Do you wish to request the book?
S.L. patient backs attempt to bring drug for MS back
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Newspaper Article
S.L. patient backs attempt to bring drug for MS back
2006
Overview
Briefly, though, [Adams] got great relief from her remitting/ relapsing MS. She twice received monthly injections of Tysabri, before Biogen Idec Inc. and Elan Corp. voluntarily suspended sales on the U.S. market in early 2005, just months after it had first received FDA approval. The move was prompted by concern that three patients had developed progressive multifocal leukoencephalopathy (PML), which is a rare and potentially deadly disease of the central nervous system. \"I am really excited for Tysabri,\" says Adams, a Salt Lake woman who also serves as a National MS Society ambassador. \"I am concerned about the safety, but I think with any of the drugs there are potential safety risks. In the two doses I did take of Tysabri, I had more energy than I'd had in years. And it happened quickly.\" The best treatments currently on the market, Adams says, only help slow progression of MS 30-35 percent. Tysabri did much better than that in earlier clinical studies and in its short-lived availability, as well as in recently published studies, which cited 68 percent fewer relapses with Tysabri than without it.
Publisher
Deseret Digital Media
Subject
